Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
39 studies found for:    " August 15, 2011":" September 14, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" August 15, 2011":" September 14, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Improving Uptake of Early Infant Diagnosis of HIV for the Prevention of Mother-to-child Transmission of HIV
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome
Intervention: Other: Text message
2 Completed Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome;   Disease Progression;   Immune System Diseases;   Malaria;   Parasitic Diseases;   Pneumonia;   Diarrhea;   Infectious Disorder of Immune System
Intervention: Other: Discontinue TMP/SMZ prophylaxis
3 Recruiting HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
Conditions: HIV Infection;   Hepatitis C
Intervention:
4 Completed The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort -
Condition: HIV-1-Associated Cognitive Motor Complex
Intervention:
5 Completed An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
Condition: Human Immunodeficiency Virus; HIV
Interventions: Drug: Darunavir/Ritonavir (DRV/r);   Drug: Efavirenz (EFV)
6 Terminated Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
Conditions: Human Immunodeficiency Virus;   Lipohypertrophy
Intervention: Drug: Raltegravir-Maraviroc
7 Active, not recruiting Drug Exposure Registry for GSK2248761, an Investigational NNRTI
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK2248761
8 Unknown  Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
Condition: HIV Infection
Intervention: Drug: Polyphenon E
9 Recruiting Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
Condition: HIV Infections
Interventions: Biological: HIVAX;   Biological: saline solution;   Biological: Saline solution
10 Withdrawn Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial
Conditions: Immune Reconstitution Inflammatory Syndrome;   Immune Reconstitution Syndrome;   Tuberculosis;   HIV-infection/Aids
Interventions: Drug: Dexamethasone;   Drug: Atorvastatin;   Drug: Naproxen;   Drug: Placebo
11 Active, not recruiting Vitamin D Supplementation in HIV
Condition: HIV-infection/Aids
Interventions: Dietary Supplement: Vitamin D3;   Dietary Supplement: Placebo
12 Recruiting Implementation of Nucleic Acid Amplification Testing Screening to Identify Acute and Early HIV Infection
Condition: Acute HIV Infection
Intervention: Other: Nucleic Acid Amplification Testing
13 Unknown  Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure
Condition: Human Immunodeficiency Virus (HIV)
Intervention: Behavioral: Enhanced Treatment Support (ETS)
14 Completed Drug Interaction Study Between Dolutegravir and Prednisone
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir;   Drug: Prednisone
15 Completed A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects
Condition: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Drug: GSK1265744 injectable suspension;   Other: Placebo to match injectable suspension
16 Active, not recruiting Screening for Tuberculosis in HIV-infected Patients Eligible for Antiretroviral Treatment
Conditions: HIV Infection;   Tuberculosis
Intervention:
17 Completed Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
Condition: HIV Infections
Interventions: Biological: Sub C gp140 Vaccine;   Biological: MF59C.1 Adjuvant;   Other: Sodium chloride
18 Completed Safety Study of Maraviroc's Effect on Human Osteoclasts
Conditions: HIV Infections;   AIDS
Intervention: Drug: Maraviroc
19 Active, not recruiting Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV;   Biological: AIDSVAX B/E;   Biological: ALVAC-HIV Placebo;   Biological: AIDSVAX B/E Placebo
20 Unknown  Efficacy of Neuro-HAART in Patients With HIV
Condition: HIV
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results    Last Page
Indicates status has not been verified in more than two years